Library

Displaying 1,176 - 1,200 of 2,412

How to Handle Myelotoxicity from Chemotherapy in 2024: From Colony-Stimulating Factors (CSF) to Agents Providing Myeloprotection to the Three Cell Lines

How to Handle Myelotoxicity from Chemotherapy in 2024: From Colony-Stimulating Factors (CSF) to Agents Providing Myeloprotection to the Three Cell Lines

By: Martin Dietrich, MD, PhD

How I Use Liquid Biopsy for GI Cancers in 2023

How I Use Liquid Biopsy for GI Cancers in 2023

By: Pashtoon Kasi, MD

Liquid Biopsy and Precision Medicine Updates in GU

Liquid Biopsy and Precision Medicine Updates in GU

By: Pedro Barata, MD

Bispecific Antibodies in Cancer Care: Actual Reality and Future Projections

Bispecific Antibodies in Cancer Care: Actual Reality and Future Projections

By: Sandip P. Patel, MD

Bispecific Antibodies in Cancer Care: Actual Reality and Future Projections

Bispecific Antibodies in Cancer Care: Actual Reality and Future Projections

By: Sandip P. Patel, MD

Targeted Therapy Updates in HCC and Cholangiocarcinoma

Targeted Therapy Updates in HCC and Cholangiocarcinoma

By: Amit Mahipal, MD

Hepatocellular and Biliary Cancers: Recent advances

Hepatocellular and Biliary Cancers: Recent advances

By: Anthony El-Khoueiry, MD

Hepatocellular and Biliary Cancers: Recent advances

Hepatocellular and Biliary Cancers: Recent advances

By: Anthony El-Khoueiry, MD

Navigating locoregional treatment options in HCC

Navigating locoregional treatment options in HCC

By: Beau Toskich, MD

Ablation with a curative intent in HCC

Ablation with a curative intent in HCC

By: Fred T. Lee, MD

Minimally Invasive to Noninvasive- HOPE 4 LIVER Results

Minimally Invasive to Noninvasive- HOPE 4 LIVER Results

By: Govindarajan Narayanan, MD

Time to Transplant – An important factor in selection of liver directed therapy

Time to Transplant – An important factor in selection of liver directed therapy

By: Jafar Golzarian, MD

Impact of c-TACE on the management of HCC

Impact of c-TACE on the management of HCC

By: Jeff Geschwind, MD

Hepatocellular Cancer and Cholangiocarcinoma Updates

Hepatocellular Cancer and Cholangiocarcinoma Updates

By: Lindsey Davis, MD

Hepatocellular Cancer and Cholangiocarcinoma Updates

Hepatocellular Cancer and Cholangiocarcinoma Updates

By: Lindsey Davis, MD

Irreversible Electroporation in Hepatocellular Carcinomas Adjacent to Critical Anatomical Structures, a Single Centre Experience

Irreversible Electroporation in Hepatocellular Carcinomas Adjacent to Critical Anatomical Structures, a Single Centre Experience

By: Nuran Seneviratne, MA, MBBS

Immunotherapy in HCC

Immunotherapy in HCC

By: Rachna T. Shroff, MD, MS, FASCO

Current role of systemic therapy in HCC

Current role of systemic therapy in HCC

By: Saeed Sadeghi, MD

Role of genomics, molecular biomarkers and AI in HCC therapy

Role of genomics, molecular biomarkers and AI in HCC therapy

By: Sarah White, MD

Cholangiocarcinoma and Hepatocellular Cancer

Cholangiocarcinoma and Hepatocellular Cancer

By: Tom Reske, MD

New Therapies for Squamous Cell and Small Cell Lung Carcinomas

New Therapies for Squamous Cell and Small Cell Lung Carcinomas

By: Alberto Chiappori, MD

State of the Art Radiation in NSCLC

State of the Art Radiation in NSCLC

By: Ana Botero, MD

State of the Art Radiation in NSCLC

State of the Art Radiation in NSCLC

By: Ana Botero, MD

Locally Advanced NSCLC Chemotherapy / Targeted Therapy / Immunotherapy

Locally Advanced NSCLC Chemotherapy / Targeted Therapy / Immunotherapy

By: Ana Velazquez Manana, MD, MSc

Locally Advanced NSCLC Chemotherapy / Targeted Therapy / Immunotherapy

Locally Advanced NSCLC Chemotherapy / Targeted Therapy / Immunotherapy

By: Ana Velazquez Manana, MD, MSc